These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 7790092)

  • 1. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli.
    Clayton MA; Clayton JM; Brown DR; Middlebrook JL
    Infect Immun; 1995 Jul; 63(7):2738-42. PubMed ID: 7790092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.
    Yu YZ; Li N; Wang RL; Zhu HQ; Wang S; Yu WY; Sun ZW
    Clin Vaccine Immunol; 2008 Dec; 15(12):1819-23. PubMed ID: 18845829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine.
    Yu YZ; Sun ZW; Li N; Wang S; Wang RL; Yu WY
    Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):261-6. PubMed ID: 18932057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of Hc fragment from Clostridium botulinum neurotoxin serotype B in Escherichia coli and its use as a good immunogen.
    Gao YL; Gao S; Kang L; Nie C; Wang JL
    Hum Vaccin; 2010 Jun; 6(6):462-6. PubMed ID: 20519939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of recombinant vaccines for botulinum neurotoxin.
    Smith LA
    Toxicon; 1998 Nov; 36(11):1539-48. PubMed ID: 9792170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate.
    Yu YZ; Li N; Zhu HQ; Wang RL; Du Y; Wang S; Yu WY; Sun ZW
    Vaccine; 2009 May; 27(21):2816-22. PubMed ID: 19428892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.
    Webb RP; Smith TJ; Wright PM; Montgomery VA; Meagher MM; Smith LA
    Vaccine; 2007 May; 25(21):4273-82. PubMed ID: 17395341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High level expression, purification and immunogenicity analysis of a protective recombinant protein against botulinum neurotoxin type E.
    Valipour E; Moosavi ML; Amani J; Nazarian S
    World J Microbiol Biotechnol; 2014 Jun; 30(6):1861-7. PubMed ID: 24469548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
    Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
    Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and evaluation of candidate subunit vaccine and novel antitoxin against botulinum neurotoxin serotype E.
    Shi DY; Liu FJ; Mao YY; Cui RT; Lu JS; Yu YZ; Dong XJ; Yang ZX; Sun ZW; Pang XB
    Hum Vaccin Immunother; 2020; 16(1):100-108. PubMed ID: 31210561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production and evaluation of a recombinant chimeric vaccine against clostridium botulinum neurotoxin types C and D.
    Gil LA; da Cunha CE; Moreira GM; Salvarani FM; Assis RA; Lobato FC; Mendonça M; Dellagostin OA; Conceição FR
    PLoS One; 2013; 8(7):e69692. PubMed ID: 23936080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination against type F botulinum toxin using attenuated Salmonella enterica var Typhimurium strains expressing the BoNT/F H(C) fragment.
    Foynes S; Holley JL; Garmory HS; Titball RW; Fairweather NF
    Vaccine; 2003 Mar; 21(11-12):1052-9. PubMed ID: 12559779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of vaccines for prevention of botulism.
    Byrne MP; Smith LA
    Biochimie; 2000; 82(9-10):955-66. PubMed ID: 11086225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes.
    Shone C; Agostini H; Clancy J; Gu M; Yang HH; Chu Y; Johnson V; Taal M; McGlashan J; Brehm J; Tong X
    Infect Immun; 2009 Jul; 77(7):2795-801. PubMed ID: 19398544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism.
    Webb RP; Smith TJ; Smith LA; Wright PM; Guernieri RL; Brown JL; Skerry JC
    Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28869522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C terminal half fragment (50 kDa) of heavy chain components of Clostridium botulinum type C and D neurotoxins can be used as an effective vaccine.
    Lee JC; Hwang HJ; Sakaguchi Y; Yamamoto Y; Arimitsu H; Tsuji T; Watanabe T; Ohyama T; Tsuchiya T; Oguma K
    Microbiol Immunol; 2007; 51(4):445-55. PubMed ID: 17446685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of a large, nontoxic fragment of botulinum neurotoxin serotype A and its use as an immunogen.
    LaPenotiere HF; Clayton MA; Middlebrook JL
    Toxicon; 1995 Oct; 33(10):1383-6. PubMed ID: 8599190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancing toxin-based vaccines against botulism.
    Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
    Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of immunodetection system for botulinum neurotoxin type B using synthetic gene based recombinant protein.
    Jain S; Ponmariappan S; Kumar O
    Indian J Med Res; 2011 Jul; 134(1):33-9. PubMed ID: 21808132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate.
    Ben David A; Torgeman A; Barnea A; Zichel R
    Protein Expr Purif; 2015 Jun; 110():122-9. PubMed ID: 25727047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.